Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Biotech companies are racing to test bacteriophages — some as found in nature, others armed with CRISPR–Cas — to destroy drug-resistant bacteria selectively while keeping the microbiome intact.
Promising gene therapy, gene editing and antisense oligonucleotide approaches herald a new era of cardiac medicine for patients with certain so-far intractable heart conditions.
RNA editing is rapidly gaining prominence as its transient and reversible changes promise a safer and more flexible option to reverse disease-causing mutations than DNA editing.
Protein engineers are drawing on rapidly evolving machine learning tools, deep reservoirs of data, and the structure-predicting firepower of AlphaFold2 to pursue more sophisticated de novo protein designs.
As farmers around the globe embrace microorganisms to treat and protect crops, ag giants sort out how they will participate in the industry, coming to different conclusions.
Natural killer cells are attractive as cancer immunotherapy agents because — unlike T cells — they evade immune rejection and do not induce cytokine storms. But capturing their activity in effective therapies remains a work in progress.
New sequencers are poised to disrupt Illumina’s dominance. Users will need to navigate the opportunities and challenges on offer in an increasingly crowded market.